A century-old debate on protein aggregation and neurodegeneration enters the clinic

Peter T. Lansbury, Hilal A. Lashuel

Research output: Contribution to journalReview article

499 Citations (Scopus)


The correlation between neurodegenerative disease and protein aggregation in the brain has long been recognized, but a causal relationship has not been unequivocally established, in part because a discrete pathogenic aggregate has not been identified. The complexity of these diseases and the dynamic nature of protein aggregation mean that, despite progress towards understanding aggregation, its relationship to disease is difficult to determine in the laboratory. Nevertheless, drug candidates that inhibit aggregation are now being tested in the clinic. These have the potential to slow the progression of Alzheimer's disease, Parkinson's disease and related disorders and could, if administered presymptomatically, drastically reduce the incidence of these diseases. The clinical trials could also settle the century-old debate about causality.

Original languageEnglish
Pages (from-to)774-779
Number of pages6
Issue number7113
Publication statusPublished - 19 Oct 2006


ASJC Scopus subject areas

  • General

Cite this